Eligible patients can now receive Jakafi for as little as $0 per month.*
 
View this email in a browser
This email is sponsored by Incyte Corporation.
  Trouble viewing this email? Please click here.
To ensure delivery to your inbox, please add ion@info.amerisourcebergen.com to your address book.
 
 
 
   
Introducing the Updated Copay/Coinsurance Program for Jakafi® (ruxolitinib)
Dear Healthcare Professional,
 
Eligible Patients Now Pay as Little as $0 Copay Monthly*
 
As part of our ongoing commitment to provide patients access to the medicines they need, we have updated our Copay/Coinsurance Program.
 
This program is available to eligible patients who have been prescribed Jakafi for any of its FDA-approved indications.
 
As of September 30, 2019, eligible patients with commercial or private prescription drug coverage will be able to receive Jakafi for as little as $0 per month. Our previous program allowed eligible patients to pay as little as $25 per month.
 
Patients who are currently enrolled in the Copay/Coinsurance Program do not need to re-enroll or take any action. They can continue to use their current program card, and their copay/coinsurance amount will automatically be reduced to $0 per month. Eligible new enrollees will receive the new $0 per month program card.
 
Financial Assistance for Patients Who Do Not Have Insurance
 
Patients who do not have prescription drug coverage for Jakafi may be eligible to receive Jakafi free of charge through the IncyteCARES Patient Assistance Program. This program helps people who do not have a prescription drug plan as well as those whose plans will not cover Jakafi. Certain conditions do apply.
 
You may enroll your eligible patients online through the IncyteCARES digital enrollment form 
 
   
  * Update effective as of September 30, 2019. Amount of savings on Jakafi will not exceed $11,977 per month and $25,000 per year, limit one 30-day supply per 30 days. You must have minimum out-of-pocket costs of $.01 to redeem this. Patients will be responsible for any out-of-pocket costs above the maximum annual and monthly program benefit. Card must be activated before use. Card is valid through December 31 of the year of activation. On January 1 of the following year, the card automatically resets and is subject to annual limits if the prescription benefit remains the same. Offer is not valid if you are uninsured or paying cash for your prescription. Offer is not valid if you are enrolled in a federal or state prescription program (including Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or any state medical or pharmaceutical assistance program). If you move or switch from commercial prescription benefit coverage to any government prescription benefit coverage, you will no longer be eligible. If you have any questions, please call 1-855-4-Jakafi (1-855-452-5234) . This card is not insurance. Offer valid only for an FDA-approved use. You are responsible for reporting receipt of program benefits to any commercial or private insurer that pays for or reimburses any part of the prescriptions filled with this program, to the extent required by law or by the insurer. You agree not to seek reimbursement from your insurer or any other third-party for all or any part of the benefit received through this offer. This card may not be sold, purchased, traded, or transferred and is void if reproduced. You agree that you will not in any way report or count the value of the Jakafi provided under this program as true out-of-pocket spending (TrOOP) under a Medicare Part D prescription drug benefit. One card per patient. No substitutions are permitted. Use of this card does not obligate you to use or continue to use Jakafi®. No other purchase and no refills are necessary. This offer is limited to one (1) per person during this offering period and is not transferable. You are responsible for all taxes. Program cards are the property of Incyte Corporation and must be turned in on request. No membership fees. Offer is good only in the United States and Puerto Rico, and void where prohibited or otherwise restricted by law. For Massachusetts residents, this offer expires on January 1, 2020 absent a change in Massachusetts law. Incyte Corporation reserves the right to rescind, revoke, or amend this program without notice.  
  Terms, conditions, and additional eligibility criteria apply. Valid prescription for Jakafi for an FDA approved indication is required. Patients insured through Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or any state or medical assistance program are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.  
   
 
For price transparency information, please click here.
 
 
Incyte Corporation is committed to maintaining the privacy of information that you or your friends share with us. For more information, please click here. If you no longer wish to receive email communications from Incyte, please click here to unsubscribe.
IncyteCARES | PO Box 221798 | Charlotte, NC 28222-1798
 
  Jakafi and the Jakafi logo are registered trademarks of Incyte.
© 2019, Incyte Corporation. MAT-INC-00682  12/19
 
Advertisement
click
This email was sent to amy.gonsuron@amerisourcebergen.com because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2020 ION Solutions. All Rights Reserved.